Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Ardelyx Inc
41XCurrent price
4.57 EUR
+0.042 EUR (+0.93%)
Last closed
4.71 USD
Company
www.ardelyx.com
ISIN
US0396971071
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
1 200 849 792 USD
Yield for 12 month
+23.33 %
1Y
3Y
5Y
10Y
15Y
41X
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 400 Fifth Avenue, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.65 USDP/E ratio
–Dividend Yield
–Current Year
+124 456 000 USD
Last Year
+52 158 000 USD
Current Quarter
+98 241 000 USD
Last Quarter
+73 222 000 USD
Current Year
+106 661 000 USD
Last Year
+48 041 000 USD
Current Quarter
+84 228 000 USD
Last Quarter
+63 217 000 USD
Key Figures 41X
1 year
3 years
5 years
10 years
EBITDA
-62 151 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-12.18 %
PEG Ratio
-0.08
Return On Equity TTM
-41.54 %
Wall Street Target Price
11.65 USD
Revenue TTM
251 848 992 USD
Book Value
0.67 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
74.2 %
Dividend Yield
–
Gross Profit TTM
15 540 000 USD
Earnings per share
-0.32 USD
Diluted Eps TTM
-0.32 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-28.82 %
Dividend Analytics 41X
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 41X
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 41X
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
4.427
Price Sales TTM
4.7681
Enterprise Value EBITDA
-27.3593
Price Book MRQ
7.5861
Financials 41X
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 41X
For 52 weeks
3.82 USD
10.13 USD
50 Day MA
6.04 USD
Shares Short Prior Month
23 053 125
200 Day MA
6.9 USD
Short Ratio
7.2
Shares Short
22 887 200
Short Percent
10.98 %
BeatStart